Crackdown On Substandard Ayurvedic Medicines

THIRUVANANTHAPURAM: Various batches of ayurvedic medicines of Rajasthan Herbal International Pvt Ltd have been found to be of substandard quality during quality tests conducted at the drug testing laboratories of the State Drugs Controller’s Department. Following this, the Ayurvedic Drugs Control Department banned the distribution and sale of these medicines.

 

Traders and hospitals holding stock of drugs should return the same to the distributor and inform the District Ayurvedic Drugs Inspectors concerned, the officials said. Name and batch number of medicines are: Pain Niwaran Churna (PNF21057), Dr Relaxi Capsule (DRG21019), Pain Niwaran Churna (PNK21089), Mood on Forever (MCE21003), Dr Relaxi Capsule (DRK21030), Dr Relaxi Oil (DOD21004), Dama Buti Churna (DBH21017), Asthalex Capsule (ALK21004).

Related Posts

  • Pharma
  • June 27, 2025
  • 176 views
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

  • Pharma
  • June 27, 2025
  • 159 views
Sun Pharma ropes in Richard Ascroft as North America CEO

Mumbai: Sun Pharma has announced the appointment of Richard Ascroft as the new North America (NAM) Chief Executive Officer (CEO). In a statement shared via LinkedIn, the company said, “We…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

MedTech Zone AMTZ Puts Vizag on the Science Map of India

MedTech Zone AMTZ Puts Vizag on the Science Map of India

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Sun Pharma ropes in Richard Ascroft as North America CEO

Sun Pharma ropes in Richard Ascroft as North America CEO

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen

Torrent Pharma shares surge 4% as JPMorgan upgrades to overweight; 18% upside seen